Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.
NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said.
Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.